Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Remi Mahmoud

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Alimentary Pharmacology & Therapeutics|December 28, 2020
Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel disease-getting to the rootRemi Mahmoud, Steven H Itzkowitz
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 6, 2022
ReplyRemi Mahmoud, Edo H J Savelkoul, Bindia Jharap, et al.
Alimentary Pharmacology & Therapeutics|January 29, 2022
Letter: loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease-authors' replyRemi Mahmoud, Johannes P D Schultheiss, Herma H Fidder, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 28, 2022
ReplyRemi Mahmoud, Johannes P D Schultheiss, Herma H Fidder, et al.
Alimentary Pharmacology & Therapeutics|December 31, 2021
Editorial: risk of loss of response to anti TNFα in patients with inflammatory bowel diseases - the longer the less? Authors' replyJohannes P D Schultheiss, Remi Mahmoud, Herma H Fidder, et al.
European Journal of Internal Medicine|September 5, 2021
Surveillance and management of colorectal dysplasia and cancer in inflammatory bowel disease: Current practice and future perspectivesAnouk M Wijnands, Remi Mahmoud, Maurice W M D Lutgens, et al.
Journal of Crohn'S & Colitis|October 30, 2020
Continuation of Anti-TNF in Patients With Ulcerative Colitis in Remission Is Not Cost-effective Compared With Treatment Withdrawal: A Markov ModelRemi Mahmoud, Chris van Lieshout, Geert W J Frederix, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 1, 2022
Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel DiseaseRemi Mahmoud, Hans-Paul Schultheiss, Jonas Louwers, et al.
European Journal of Cancer (Oxford, England : 1990)|May 6, 2018
Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic reviewKaitlyn K H Goey, Remi Mahmoud, Halfdan Sørbye, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 26, 2019
Association Between Indefinite Dysplasia and Advanced Neoplasia in Patients With Inflammatory Bowel Diseases Undergoing SurveillanceRemi Mahmoud, Shailja C Shah, Joana Torres, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Alimentary Pharmacology & Therapeutics|December 28, 2020
Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel disease-getting to the rootRemi Mahmoud, Steven H Itzkowitz
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 6, 2022
ReplyRemi Mahmoud, Edo H J Savelkoul, Bindia Jharap, et al.
Alimentary Pharmacology & Therapeutics|January 29, 2022
Letter: loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease-authors' replyRemi Mahmoud, Johannes P D Schultheiss, Herma H Fidder, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 28, 2022
ReplyRemi Mahmoud, Johannes P D Schultheiss, Herma H Fidder, et al.
Alimentary Pharmacology & Therapeutics|December 31, 2021
Editorial: risk of loss of response to anti TNFα in patients with inflammatory bowel diseases - the longer the less? Authors' replyJohannes P D Schultheiss, Remi Mahmoud, Herma H Fidder, et al.
European Journal of Internal Medicine|September 5, 2021
Surveillance and management of colorectal dysplasia and cancer in inflammatory bowel disease: Current practice and future perspectivesAnouk M Wijnands, Remi Mahmoud, Maurice W M D Lutgens, et al.
Journal of Crohn'S & Colitis|October 30, 2020
Continuation of Anti-TNF in Patients With Ulcerative Colitis in Remission Is Not Cost-effective Compared With Treatment Withdrawal: A Markov ModelRemi Mahmoud, Chris van Lieshout, Geert W J Frederix, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 1, 2022
Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel DiseaseRemi Mahmoud, Hans-Paul Schultheiss, Jonas Louwers, et al.
European Journal of Cancer (Oxford, England : 1990)|May 6, 2018
Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic reviewKaitlyn K H Goey, Remi Mahmoud, Halfdan Sørbye, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 26, 2019
Association Between Indefinite Dysplasia and Advanced Neoplasia in Patients With Inflammatory Bowel Diseases Undergoing SurveillanceRemi Mahmoud, Shailja C Shah, Joana Torres, et al.
Pageof 2